Why did LTRN's EPS remain flat throughout 2024?

The EPS of Lantern Pharma Inc (LTRN) remained flat throughout 2024 due to a combination of factors: 1. **Consistent Financial Performance**: Despite fluctuations in net income, Lantern Pharma has maintained a relatively stable EPS throughout 2024. This indicates a consistent financial performance, which is a positive sign for investors. 2. **Revenue Contribution**: The lack of revenue contribution to the EPS can be attributed to the company's focus on research and development, as evidenced by the increased R&D expenses in Q3 2024. This focus on innovation may have temporarily impacted profitability but is expected in a biotech company. 3. **Cost Management**: The company's cost management has been effective, as evidenced by the decrease in general and administrative expenses in Q2 2024. This suggests that while the company is investing in R&D, it is also managing other expenses to maintain financial stability. 4. **Investor Perspective**: From an investor perspective, the flat EPS may not be a significant concern if it is accompanied by positive developments in the company's pipeline and strategic initiatives, as seen with the patent grant and clinical trial updates. In conclusion, the flat EPS of LTRN throughout 2024 can be attributed to a combination of consistent financial performance, lack of revenue contribution, effective cost management, and investor perspective. These factors, coupled with the company's strategic initiatives, provide a balanced view of Lantern Pharma's financial health and growth prospects.